2763 completed. 2763 Phase 2, 611 Phase 1, 58 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2763 | Completed 2763 |
| Phase 1 | 611 | Completed 611 |
| Phase 3 | 58 | Completed 58 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Werewolf Therapeutics, Inc. | 24 | 2025-04-21 | 2026-10-19 |
| A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients EI-1071 tablet, oral - Mild, Moderate, or Severe Alzheimer's Disease | Phase 2 | Completed | Elixiron Immunotherapeutics Inc. | 7 | 2024-12-16 | 2026-09-23 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1 - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Hutchmed | 61 | 2024-11-05 | 2026-09-24 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG Ficus septica exudate (antiseptic plant exudates), Pterocarpus indicus exudate, Curcuma longa aqueous extract - Cutaneous Ulcer Disease, Skin Sores | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 370 | 2024-10-04 | 2024-11-29 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) DZD8586 - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 59 | 2024-03-13 | 2026-08-04 |
| An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
| Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. AON-D21, Placebo - Community-acquired Pneumonia | Phase 2 | Completed | Aptarion Biotech AG | 150 | 2024-02-02 | 2026-03-18 |
| Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab Vedotin, Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Peng Liu | 30 | 2023-12-20 | 2026-10-14 |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL Hypericin, Mechlorethamine Topical Gel - Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 2 | Completed | Soligenix | 10 | 2023-12-05 | 2025-08-20 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Completed | Ellen Kim, MD | 10 | 2023-08-21 | 2026-02-09 |
| Evaluating Different Doses of Orelabrutinib in MCL Orelabrutinib High dose, Orelabrutinib Low dose - Mantle Cell Lymphoma | Phase 2 | Completed | InnoCare Pharma Inc. | 40 | 2023-08-18 | 2026-06-11 |
| A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 - Chronic Lymphocytic Leukemia, COVID-19 Infection | Phase 2 | Completed | City of Hope Medical Center | 47 | 2023-08-01 | 2026-09-09 |
| Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas Chidamide - T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Completed | Zhejiang University | 44 | 2023-07-15 | 2025-12-05 |
| Janus Kinase Inhibition in Sarcoidosis Abrocitinib 200 mg - Sarcoidosis | Phase 2 | Completed | Yale University | 10 | 2023-06-01 | 2026-09-21 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant GPC-100, Propranolol, G-CSF - Multiple Myeloma | Phase 2 | Completed | GPCR Therapeutics, Inc. | 30 | 2023-02-13 | 2026-02-12 |
Showing 20 of 2763. Sign in to see all of them.
Multiple Myeloma (747) · Lymphoma (696) · Lymphoma, Non-Hodgkin (556) · Leukemia, Lymphocytic, Chronic, B-Cell (509) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (452) · Lymphoma, Large B-Cell, Diffuse (394) · Leukemia (385) · Lymphoma, Follicular (383) · Hodgkin Disease (355) · Lymphoma, Mantle-Cell (336) · Leukemia, Myeloid, Acute (239) · Recurrence (238) · Lymphoma, B-Cell, Marginal Zone (226) · Burkitt Lymphoma (213) · Neoplasms, Plasma Cell (193)
Immune System Diseases (2752) · Hemic and Lymphatic Diseases (2738) · Immunoproliferative Disorders (2714) · Neoplasms by Histologic Type (2698) · Neoplasms (2624) · Lymphatic Diseases (2169) · Hematologic Diseases (1622) · Lymphoma (902) · Cardiovascular Diseases (870) · Paraproteinemias (869) · Vascular Diseases (867) · Blood Protein Disorders (859) · Hemorrhagic Disorders (858) · Hemostatic Disorders (850)
Cyclophosphamide (495) · Rituximab (451) · Dexamethasone (331) · Lenalidomide (226) · Etoposide (210) · Bortezomib (209) · Filgrastim (206) · Vincristine (201) · Doxorubicin (187) · Melphalan (185) · Prednisone (172) · Cytarabine (167) · fludarabine phosphate (166) · Peripheral Blood Stem Cell Transplantation (144) · Methotrexate (143)
M.D. Anderson Cancer Center (148) · National Cancer Institute (NCI) (148) · Memorial Sloan Kettering Cancer Center (87) · Fred Hutchinson Cancer Center (80) · Mayo Clinic (60) · Alliance for Clinical Trials in Oncology (41) · Dana-Farber Cancer Institute (37) · Novartis Pharmaceuticals (37) · Celgene (33) · GlaxoSmithKline (30) · Hoffmann-La Roche (29) · National Heart, Lung, and Blood Institute (NHLBI) (25) · SWOG Cancer Research Network (25) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (25) · H. Lee Moffitt Cancer Center and Research Institute (24)
United States (1876) · France (257) · Germany (246) · Italy (231) · Canada (215) · United Kingdom (193) · Spain (160) · Australia (117) · Belgium (104) · China (84) · Netherlands (84) · South Korea (81) · Poland (78) · Japan (72) · Austria (70)
Brenda Sandmaier (9) · Craig Moskowitz, MD (9)
PMID 34515338, PMID 32499241, PMID 35622074, PMID 23524640, PMID 27209293, PMID 31401903, PMID 23065508, PMID 29358183, PMID 35549810, PMID 38502198, PMID 40135712, PMID 17242396, PMID 18596230, PMID 23834234, PMID 26373676, PMID 27282998, PMID 30125215, PMID 30957581, PMID 31050355, PMID 31221778, PMID 32632956, PMID 32770353, PMID 35787017, PMID 35882475, PMID 37981564, PMID 40156952, PMID 18997171, PMID 19451441, PMID 19667400, PMID 20661232, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24224624, PMID 24862638, PMID 25381051, PMID 25628469, PMID 26181891, PMID 26182309, PMID 26308596, PMID 26690712, PMID 26813675, PMID 27307294, PMID 27750483, PMID 29025767, PMID 29437592
P30CA015704 (41), P30CA015083 (38), U10CA031946 (33), U10CA032102 (30), 2015 (24), 2009 (22), 2014 (21), 2017 (21), 2016 (20), 2005 (19), 2008 (19), P30CA006973 (15), P30CA016672 (15), P30CA033572 (14), P30CA043703 (14)